Key Updates Proposed for EU GMP Guidelines

Recent revisions to the EU Good Manufacturing Practice (GMP) guidelines are being driven by concerns over nitrosamine impurities, the implementation of ICH Q9(R1) Quality Risk Management, stronger data governance requirements, and the growing use of artificial intelligence in pharmaceutical manufacturing.

The updated Chapter 1 – Pharmaceutical Quality System emphasizes stronger Quality Risk Management (QRM) and Knowledge Management. New provisions encourage companies to use knowledge systems alongside risk management to detect potential manufacturing issues early and support continuous improvement. Clarifications have also been introduced for Product Quality Review (PQR) processes, particularly for products manufactured in small batches.

Chapter 4 – Documentation now highlights the management of digital, paper, and hybrid records while strengthening data integrity and electronic signature requirements.

Updates to Annex 6, Annex 11, and Annex 15 focus on practical batch certification, improved lifecycle management of computerized systems, and stronger validation practices—especially following nitrosamine contamination incidents.

A new Annex 22 will introduce regulatory expectations for the safe use of artificial intelligence and machine learning in pharmaceutical production.

04-03-2026